Several clinical trials using BCMA-targeted CAR-T therapy or even BCMA/CD19 dual-targeted CAR-T therapy are planned in refractory ARDs, including SLE, Sjögren's syndrome, immune-mediated necrotizing myopathies, scleroderma and vasculitis (Table 3). This evidence concerns the gene CD19 and systemic lupus erythematosus.